Occam Places Bryan Stuart as CEO of Atavistik
Atavistik, a computational biology platform company, and Lux Capital/Column Group investment, is focused on developing transformative small molecule therapeutics by revolutionizing the discovery and interrogation of new allosteric protein-metabolite interactions.
Bryan Stuart joins a formidable constellation of investors and operators, including Chairman John Josey, former CEO of Peloton Therapeutics which sold to Merck for over $1B, and Marion Dorsch, R&D heavyweight and former scientific leader at Blueprint and Agios.
Stuart was most recently CEO of Fulcrum, where he initially served as Chief Operating Officer. Prior to Fulcrum, he served as President and CEO of Yarra Therapeutics (a subsidiary of Array BioPharma) and CEO of Kastle Therapeutics. Previously, Stuart served as Chief Business Officer of Civitas Therapeutics (acquired by Acorda Therapeutics) and also led business development, corporate development, and strategy at both EKR Therapeutics (acquired by Chiesi Farmaceutici) and Ovation Pharmaceuticals (acquired by Lundbeck A/S).
Stuart earned his MBA from the Kellogg School at Northwestern University and his bachelor’s degree from the University of Illinois.
Recent Placements
Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.